Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors
Authors:
- Julienne E. BowerJBJulienne E. Bower
- Patricia A. GanzPGPatricia A. Ganz
- Najib AzizNANajib Aziz
- John L. FaheyJFJohn L. Fahey
Top Cited Papers
- 1 July 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Psychosomatic Medicine
- Vol. 64 (4) , 604-611
Abstract
Fatigue is a common problem among cancer patients and survivors, yet the mechanisms underlying the occurrence and persistence of this symptom are not known. Activation of the immune system may evoke feelings of fatigue, which are mediated by proinflammatory cytokines. We examined whether fatigued breast cancer survivors would show elevations in proinflammatory cytokines and markers of cytokine activity compared with nonfatigued survivors. Differences in lymphocyte subsets, cortisol, and behavioral symptoms associated with proinflammatory cytokines were also assessed. Forty breast cancer survivors (20 fatigued, 20 nonfatigued) provided blood samples at visits scheduled to control for diurnal variability. Cytokines, soluble markers of cytokine activity, and cortisol were measured by immunoassay and lymphocyte subsets by flow cytometry. Participants also completed questionnaires measuring demographic, medical, and behavioral variables. Fatigued breast cancer survivors had significantly higher serum levels of several markers associated with proinflammatory cytokine activity than nonfatigued survivors, including interleukin-1 receptor antagonist (IL-1ra), soluble tumor necrosis factor receptor type II (sTNF-RII), and neopterin. They were also more likely to report behavioral problems that co-occur with fatigue in the context of immune activation. Fatigued survivors had significantly lower serum levels of cortisol than the nonfatigued group as well as differences in two lymphocyte populations. Fatigued breast cancer survivors showed elevations in serum markers associated with proinflammatory cytokine activity an average of 5 years after diagnosis. Results suggest mechanisms through which enduring immune activation may occur, including alterations in cortisol and in lymphocyte subsets.Keywords
This publication has 43 references indexed in Scilit:
- INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in BiologyAnnual Review of Immunology, 1998
- Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosisBrain, 1997
- The rand 36‐item health survey 1.0Health Economics, 1993
- Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancerJournal of Pain and Symptom Management, 1993
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Fatigue syndrome due to localized radiationJournal of Pain and Symptom Management, 1992
- Changes of lymphocyte subsets after local irradiation for early stage breast cancer and seminoma testis: long-term increase of activated (HLA-DR+) T cells and decrease of “naive” (CD4-CD45R) T lymphocytesEuropean Journal of Cancer, 1992
- Biological basis of the behavior of sick animalsNeuroscience & Biobehavioral Reviews, 1988
- Neopterin as a marker for activated cell-mediated immunity: Application in HIV infectionImmunology Today, 1988
- Adjuvant Radiation Therapy Compared with Cyclic Chemotherapy in Patients with Mammary Carcinoma: I. Changes of blood lymphocyte subpopulationsActa Radiologica: Oncology, 1981